Clinical Trial Update: A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. [Phase 2]

View source ↗

Summary

A Phase 2 rollover study of tremelimumab for patients who had received it in other protocols, to provide continued access until it becomes commercially availabl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Colorectal Neoplasms, Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-28